Login
Home / ARDS : OTC
Follow Compare
AI Analysis Fundamentals Valuation Video Analysis News Similar
Quarterly Quarterly (TTM) Annually

AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Aridis Pharmaceuticals, Inc.

$0 -$0.00 (-50.00%)
OTC · 11 Sep 2026 20:00 UTC
Previous Close
$0
Day Range
$0$0
Year Range
$0$0.05
Market Cap
4.46K
AVG Volume
14.42K
Trailing/Forward PE
-0/0
PEG ratio
-0
Dividend Yield
-
Next Earnings Date
2026-11-02
Primary Exchange
Other OTCUS
Revenue (USD)
05M10M15M20M21 Q221 Q321 Q422 Q122 Q222 Q322 Q423 Q123 Q223 Q3
Net Income (USD)
-30M-20M-10M010M20M21 Q221 Q321 Q422 Q122 Q222 Q322 Q423 Q123 Q223 Q3
Operating Income (USD)
-30M-20M-10M010M20M21 Q221 Q321 Q422 Q122 Q222 Q322 Q423 Q123 Q223 Q3
EBITDA (USD)
-30M-20M-10M010M20M21 Q221 Q321 Q422 Q122 Q222 Q322 Q423 Q123 Q223 Q3
Cash Flows (USD)
-15M-10M-5M021 Q221 Q321 Q422 Q122 Q222 Q322 Q423 Q123 Q223 Q3
EPS (USD)
-2-10121 Q221 Q321 Q422 Q122 Q222 Q322 Q423 Q123 Q223 Q3
Expenses (USD)
-10M010M20M30MR&DSG&ACapex21 Q221 Q321 Q422 Q122 Q222 Q322 Q423 Q123 Q223 Q3
Cash & Debt (USD)
05M10M15M20MCashLong Term DebtShort Term Debt21 Q221 Q321 Q422 Q122 Q222 Q322 Q423 Q123 Q223 Q3
Debt ratios
-10-7.5-5-2.502.521 Q221 Q321 Q422 Q122 Q222 Q322 Q423 Q123 Q223 Q3
Margins
0%50%100%150%18 Q419 Q119 Q420 Q221 Q221 Q321 Q422 Q223 Q223 Q3
Return on Capital
-200%0%200%400%600%21 Q221 Q321 Q422 Q122 Q222 Q322 Q423 Q123 Q223 Q3
Shares Outstanding
010M20M30M40M21 Q221 Q321 Q422 Q122 Q222 Q322 Q423 Q123 Q223 Q3
Book Value Per Share (USD)
-3-2-1021 Q221 Q321 Q422 Q122 Q222 Q322 Q423 Q123 Q223 Q3
Total Assets (USD)
010M20M30M21 Q221 Q321 Q422 Q122 Q222 Q322 Q423 Q123 Q223 Q3
Employee Count
01020304020182019202020212022
Free Cash Flow Yield
-60000000%-40000000%-20000000%0%med -479147.92%Jan 25May 25Sep 25Jan 26May 26Sep 26
Price to Sales
0000.01med 0Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
Price to Book
0204060med 4.55Nov 18Feb 19May 19Aug 19Nov 19Feb 20May 20
Aridis Pharmaceuticals, Inc.
ARDS
Stockpicker

Video analysis: ARDS

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: ARDS

Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer

gurufocus.com · 13 Sep 2026

Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer

Johnson and Johnson's RYBREVANTÂ (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positi

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.